Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Dose Optimization in Advanced Melanoma
NCT06116461Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2022
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nivolumab in melanoma, sponsored by Erasmus MC. Primary endpoint: Difference between the nivolumab mean trough level after 3 reduced doses and after the first dose of 6 mg/kg or 480 mg at 4 months. Started Jan 2022; status: recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06116461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06116461.